Long-term blockade of L/N-type Ca 2+ channels by cilnidipine ameliorates repolarization abnormality of the canine hypertrophied heart

British Journal of Pharmacology

Volumn 158, Issue 5, 2009, Pages 1366-1374

  Takahara, A ^a,b   Nakamura, Y ^a   Wagatsuma, H ^b   Aritomi, S ^b   Nakayama, A ^b   Satoh, Y ^a   Akie, Y ^c   Sugiyama, A ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

^b AJINOMOTO CO INC   (Japan)

^c Sugi Institute of Biological Science   (Japan)

Author keywords

Chronic atrioventricular block dog; Cilnidipine; Hypertrophied heart; Long QT interval; N type Ca 2+ channel

Indexed keywords

ADRENALIN; ALDOSTERONE; AMLODIPINE; ANGIOTENSIN II; CALCIUM CHANNEL L TYPE; CALCIUM CHANNEL N TYPE; CANDESARTAN; CILNIDIPINE; NORADRENALIN;

ACTION POTENTIAL; ADRENALIN BLOOD LEVEL; ALDOSTERONE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; ATRIOVENTRICULAR BLOCK; BLOOD SAMPLING; CARDIOVASCULAR EFFECT; CHRONIC DISEASE; CONTROLLED STUDY; DOG; HEART BEAT; HEART ELECTROPHYSIOLOGY; HEART HYPERTROPHY; HEART REPOLARIZATION; NONHUMAN; NORADRENALIN BLOOD LEVEL; PRIORITY JOURNAL; QT INTERVAL; SUDDEN DEATH; TREATMENT DURATION;

ACTION POTENTIALS; AMLODIPINE; ANGIOTENSIN II; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; ANIMALS; ATRIOVENTRICULAR BLOCK; BENZIMIDAZOLES; CALCIUM CHANNEL BLOCKERS; CALCIUM CHANNELS, L-TYPE; CALCIUM CHANNELS, N-TYPE; CARDIOMEGALY; CHRONIC DISEASE; DIHYDROPYRIDINES; DOGS; ELECTROCARDIOGRAPHY; EPINEPHRINE; FEMALE; MALE; NEUROTRANSMITTER AGENTS; NOREPINEPHRINE; TETRAZOLES; TIME FACTORS;

EID: 70849129478     PISSN: 00071188     EISSN: 14765381     Source Type: Journal    
DOI: 10.1111/j.1476-5381.2009.00407.x     Document Type: Article

References (55)

1. Alexander SPH, Mathie A, Peters JA (2008). Guide to Receptors and Channels (GRAC), 3rd ed. Br J Pharmacol 153 (Suppl. 2): S1-S209.
2. Antzelevitch C (2007). Ionic, molecular, and cellular bases of QT-interval prolongation and torsade de pointes. Europace 9 (Suppl. 4): iv4-15.
3. Antzelevitch C, Belardinelli L, Zygmunt AC, Burashnikov A, Di Diego JM, Fish JM et al (2004). Electrophysiological effects of ranolazine, a novel antianginal agent with antiarrhythmic properties. Circulation 110: 904-910. (Pubitemid 39136212)
4. Aritomi S, Nogi Y, Koganei H, Mitsui A, Konda T, Yoshlmura M (2007). The role of N-type calcium channels in regulating aldosterone secretion in H295R human adrenocortical cells. J Am Soc Nephrol 18: 155A.
5. + current density in rat ventricular myocytes. J Physiol 537: 151-160.
6. Brennan M, Palaniswami M, Kamen P (2001). Do existing measures of Poincaré plot geometry reflect nonlinear features of heart rate variability? IEEE Trans Biomed Eng 48: 1342-1347. (Pubitemid 32988575)
7. Caballero R, Delpón E, Valenzuela C, Longobardo M, González T, Tamargo J (2001). Direct effects of candesartan and eprosartan on human cloned potassium channels involved in cardiac repolarization. Mol Pharmacol 59: 825-836. (Pubitemid 32274011)
8. Covic A, Diaconita M, Gusbeth-Tatomlr P, Covic M, Botezan A, Ungureanu G et al (2002). Haemodialysis increases QTc interval but not QTc dispersion in ESRD patients without manifest cardiac disease. Nephrol Dial Transplant 17: 2170-2177. (Pubitemid 35446674)
9. KI potassium current downregulation. J Mol Cell Cardiol 42: 63-70.
10. Dritsas A, Sbarouni E, Gilligan D, Nihoyannopoulos P, Oakley CM (1992). QT-Interval abnormalities in hypertrophic cardiomyopathy. Clin Cardiol 15: 739-742.
11. Fujita T, Ando K, Nishimura H, Ideura T, Yasuda G, Isshiki M et al.; Cilnidipine versus Amlodipine Randomised Trial for Evaluation in Renal Disease (CARTER) Study Investigators. (2007). Antlproteinuric effect of the calcium channel blocker cilnidipine added to reninangiotensin inhibition in hypertensive patients with chronic renal disease. Kidney Int 72: 1543-1549.
12. 2+ channels in evoked release of norepinephrine from sympathetic neurons. Science 239: 57-61.
13. Ito K, Shiomi M, Kito G (1995). Effects of the non-peptlde angiotensin II receptor antagonist TCV-116 on systemic and renal hemodynamics in dogs with renal hypertension. Hypertens Res 18: 69-75.
14. Karlberg BE (1983). Adrenergic regulation of renin release and effects on angiotensin and aldosterone. Acta Med Scand Suppl 672: 33-40.
15. Konda T, Enomoto A, Takahara A, Yamamoto H (2006). Effects of L/N-type calcium channel antagonist, cilnidipine on progressive renal injuries in Dahl salt-sensitive rats. Biol Pharm Bull 29: 933-937.
16. Konda T, Enomoto A, Aritomi S, Koganei H, Ogawa T, Nitta K (2009). Different effects of L/N-type and L-type calcium channel blockers on the renin-angiotensin-aldosterone system in SHR/Izm. Am J Nephrol 30: 155-161.
17. Lengyel C, Virág L, Bíró T, Jost N, Magyar J, Biliczki P et al. (2007). Diabetes mellitus attenuates the repolarization reserve in mammalian heart. Cardiovasc Res 73: 512-520. (Pubitemid 46073948)
18. Lu HR, Vlaminckx E, Van de Water A, Gallacher DJ (2006). Calmodulin antagonist W-7 prevents sparfloxacin-induced early afterdepolarizations (EADs) in isolated rabbit purkinje fibers: importance of beat-to-beat instability of the repolarization. J Cardiovasc Electrophysiol 17: 415-422.
19. Mazur A, Roden DM, Anderson ME (1999). Systemic administration of calmodulin antagonist W-7 or protein kinase A inhibitor H-8 prevents torsade de pointes in rabbits. Circulation 100: 2437-2442.
20. Molderings GJ, Likungu J, Göthert M (2000). N-type calcium channels control sympathetic neurotransmission in human heart atrium. Circulation 101: 403-407. (Pubitemid 30067397)
21. 2+ channel blocker, on adrenal catecholamine secretion in anesthetized dogs. J Cardiovasc Pharmacol 32: 479-484.
22. Peschar M, Vernooy K, Vanagt WY, Reneman RS, Vos MA, Prinzen FW (2003). Absence of reverse electrical remodeling during regression of volume overload hypertrophy in canine ventricles. Cardiovasc Res 58: 510-517. (Pubitemid 36694436)
23. Raizada V, Skipper B, Luo W, Garza L, Hines CW, Harford AA et al (2005). Renin-angiotensin polymorphisms and QTc interval prolongation in end-stage renal disease. Kidney Int 68: 1186-1189. (Pubitemid 43246435)
24. Reddy HK, Wasson S, Koshy SK, Komatireddy R (2003). Structural correlates of electrical remodeling in ventricular hypertrophy. Cardiovasc Res 58: 495-497. (Pubitemid 36694434)
25. Roden DM (1998). Taking the 'idio' out of 'idiosyncratic': predicting torsades de pointes. Pacing Clin Electrophyslol 21: 1029-1034.
26. Sakata K, Shirotani M, Yoshida H, Nawada R, Obayashi K, Togi K et al (1999). Effects of amlodipine and cilnidipine on cardiac sympathetic nervous system and neurohormonal status in essential hypertension. Hypertension 33: 1447-1452. (Pubitemid 29282669)
27. Schoenmakers M, Ramakers C, van Opstal JM, Leunissen JD, Londoño C, Vos MA (2003). Asynchronous development of electrical remodeling and cardiac hypertrophy in the complete AV block dog. Cardiovasc Res 59: 351-359. (Pubitemid 37272029)
28. Singh JP, Johnston J, Sleight P, Bird R, Ryder K, Hart G (1997). Left ventricular hypertrophy in hypertensive patients is associated with abnormal rate adaptation of QT interval. J Am Coll Cardiol 29: 778-784. (Pubitemid 27128251)
29. Sugiyama A, Ishida Y, Satoh Y, Aoki S, Hori M, Akie Y et al. (2002). Electrophysiological, anatomical and histological remodeling of the heart to AV block enhances susceptibility to arrhythmogenic effects of QT-prolonging drugs, Jpn J Pharmacol 88: 341-350. (Pubitemid 34302986)
30. Swynghedauw B, Balllard C, Milliez P (2003). The long QT interval is not only inherited but is also linked to cardiac hypertrophy.J Mol Med 81: 336-345. (Pubitemid 36783237)
31. 2+ channel blocker with inhibitory action on sympathetic neurotransmitter release. Cardiovasc Ther 27: 124-139.
32. Takahara A, Dohmoto H, Hisa H, Satoh S, Yoshimoto R (1997). Cilnidipine attenuates renal nerve stimulation-induced renal vasoconstriction and antinatriuresis in anesthetized dogs, Jpn J Pharmacol 75: 27-32. (Pubitemid 27462572)
33. 2+ channel blocker cilnidipine assessed in the chronic atrioventricular conduction block dogs. J Pharmacol Sci.96: 219-223.
34. 1 blocker terfenadine-induced torsades de pointes arrhythmias. Br J Pharmacol 147: 634-641.
35. Takahara A, Sugiyama A, Satoh Y, Iwasaki H, Nakamura Y, Hashimoto K (2007a). Cardiovascular profile of the canine torsades de pointes arrhythmia model assessed by echocardiographic and haemodynamic methods. Basic Clin Pharmacol Toxicol 101: 35-40. (Pubitemid 46934647)
36. 2+ channel blocker cilnidipine in anesthetized dogs. Eur J Pharmacol 565: 166-170.
37. Takahara A, Nakamura Y, Sugiyama A (2008). Beat-to-beat variability of repolarization differentiates the extent of torsadogenic potential of multl ion channel-blockers bepridil and amiodarone. Eur J Pharmacol 596: 127-131.
38. 2+ antagonist, cilnidipine, against cardiac hypertrophy and dysfunction in stroke-prone, spontaneously hypertensive rats. Can J Physiol Pharmacol 83: 785-790.
39. Thomsen MB, Verduyn SC, Stengl M, Beekman JD, de Pater G, van Opstal J et al (2004). Increased short-term variability of repolarization predicts d-sotalol-induced torsades de pointes in dogs. Circulation 110: 2453-2459. (Pubitemid 39407353)
40. Thomsen MB, Truin M, van Opstal JM, Beekman JD, Volders PG, Stengl M et al. (2005). Sudden cardiac death in dogs with remodeled hearts is associated with larger beat-to-beat variability of repolarization. Basic Res Cardiol 100: 279-287. (Pubitemid 41348819)
41. Thomsen MB, Volders PG, Beekman JD, Matz J, Vos MA (2006). Beatto-beat variability of repolarization determines proarrhythmic outcome in dogs susceptible to drug-induced torsades de pointes. J Am Coll Cardiol 48: 1268-1276. (Pubitemid 44345129)
42. Tomaselli GF, Marbán E (1999). Electrophysiological remodeling in hypertrophy and heart failure. Cardiovasc Res 42: 270-283. (Pubitemid 29243156)
43. Topilski I, Rogowski O, Rosso R, Justo D, Copperman Y, Glikson M et al. (2007). The morphology of the QT interval predicts torsade de pointes during acquired bradyarrhythmias. J Am Coll Cardiol 49: 320-328. (Pubitemid 46110956)
44. 2+ current by cilnidipine (FRC-8653) in acutely dissociated rat sympathetic neurones. Br J Pharmacol 122: 37-42.
45. Uneyama H, Uchida H, Konda T, Yoshimoto R (1999). Cilnidipine: preclinical profile and clinical evaluation. Cardiovasc Drug Rev 17: 341-357. (Pubitemid 30161292)
46. Verduyn SC, Ramakers C, Snoep G, Leunissen JD, Wellens HJ, Vos MA (2001). Time course of structural adaptations in chronic AV block dogs: evidence for differential ventricular remodeling. Am J Physiol 280: H2882-H2890. (Pubitemid 32553333)
47. Verduyn SC, Vos MA, Gorgels AP, van der Zande J, Leunissen JD, Wellens HJ (1995). The effect of flunarizine and ryanodine on acquired torsades de pointes arrhythmias in the intact canine heart. J Cardiovasc Electrophysiol 6: 189-200.
48. + currents in dogs with chronic complete atrioventricular block and acquired torsades de pointes. Circulation 100: 2455-2461.
49. Vos MA, de Groot SH, Verduyn SC, van der Zande J, Leunissen HD, Cleutjens JP et al. (1998). Enhanced susceptibility for acquired torsade de pointes arrhythmias in the dog with chronic, complete AV block is related to cardiac hypertrophy and electrical remodeling. Circulation 98: 1125-1135.
50. Wang YH, Shi CX, Dong F, ShengJW, Xu YF (2008). Inhibition of the rapid component of the delayed rectifier potassium current in ventricular myocytes by angiotensin II via the ATI receptor. Br J Pharmacol 154: 429-439. (Pubitemid 351670608)
51. Wong KY, McSwiggan S, Kennedy NS, Wong SY, Gavin A, MacWalter RS et al (2005). Spectrum of cardiac abnormalities associated with long QT in stroke survivors. Heart 91: 1306-1310. (Pubitemid 41360948)
52. Yamanaka K, Suzuki M, Munehasu S, Ishiko J (1991). Antihypertensive effects of amlodipine, a new calcium antagonist. Folia Pharmacol Jpn 97: 115-126.
53. Yoshida H, Sugiyama A, Satoh Y, Ishida Y, Yoneyama M, Kugiyama K et at. (2002). Comparison of the in vivo electrophysiological and proarrhythmic effects of amiodarone with those of a selective class III drug, sematilide, using a canine chronic atrioventricular block model. Circ J 66: 758-762.
54. Yoshimoto R, Hirasawa A, Dohmoto H, Iwata S (1992). Antihypertensive effects of 2-methoxyethyl (E)-3-phenyl-2-propen-1-yl(±)-1,4-dihydro-2,6 dimethyl-4-(3-nitrophenyl) pyridine-3,5-dicar boxylate (FRC-8653), a novel dihydropyridine derivative, in renovascular hypertensive dogs. Pharmacometrics 44: 45-51.
55. to in epicardial and endocardial ventricular myocytes from the canine heart. Circ Res 86: 1062-1068.